The 25th AGITG Annual Scientific Meeting was held for the first time in Aotearoa New Zealand and attended by over 350 delegates from oncological practice, community and industry.

Held in Ōtautahi/Christchurch on 13–16 November 2023, this year’s ASM focused on the theme ‘Navigating Pathways to Equity in GI Cancer Research’, intended to address the pressing need to extend access and increase equity to therapeutic options across regional, rural and remote areas, as well as culturally diverse and First Nations populations.

Read on for our overview of the 2023 Meeting – or listen to The Oncology Podcast‘s wrap-up episode, featuring Co-Convenor Dr Ben Lawrence and International Invited Faculty A/Prof Katherine Garman.

Go to: Day 1 | Day 2 | Day 3 | Day 4 | Image gallery

#AGITG23: Day Two

Tuesday, 14 November 2023

Delegates of the ASM were welcomed by senior members of the Kai Tahu Iwi on their whenua by mihi whakatau, as accorded by cultural protocol.

Opening Plenary

Thank you to AstraZeneca for sponsoring this session.

Delegates headed into the Opening Plenary, with Prof Jonathan Koea presenting his keynote presentation, Taiporohenui: Cease the Tide of Wrongdoing, and Prof Lisa Jackson-Pulver presenting hers, Indigenous Equity – This is a Crisis. A panel discussion followed.

Early gastric cancer (adenocarcinoma and NETs)

Thank you to Bristol Myers Squibb for sponsoring this session.

Trials showcased: NEO-CREATE, SSGXXII

Abstract presented: Treatment intensification and outcomes post neo-adjuvant chemo-radiotherapy (NACRT) or perioperative chemotherapy and surgery in patients with early-stage oesophago-gastric cancers (OGC) – clinical audit – Lavanya Lingam

The first focus of the day was gastric cancer. Spotlighting familial gastric cancer and the CDH1 gene were presentations by Prof Parry Guilford and A/Prof Karyn Paringatai, and Erin Gardner and Prof Jeremy Rossaak. A surgical spotlight by Dr Janice Pasieka was followed by A/Prof Katherine Garman’s translational keynote, Diversity and Inclusion in Translational Gastric Cancer Research.

Poster walk

This year, the ASM introduced walking poster viewing and discussion sessions, with one led on Tuesday by Prof David Goldstein.

Pancreatic cancer

Trials showcased: MASTERPLAN (including substudies MASTERPLAN Microbiome and RANDOMS), NEO-IMPACT, DYNAMIC–Pancreas

The second focus of the day was pancreatic cancer, with emphasis on multidisciplinary collaboration and platforms. Multidisciplinary cases from the ANZ region were delivered by firstly Meredith Cummins and Dr Michelle Sullivan, then Dr Pranavan Palamuthusingam and Dr Saxon Connor. Prof Diane Simeone delivered the surgical oncology keynote, New Platforms to Improve Survival in Pancreatic Cancer, and introduced the PRECEDE Consortium to attending delegates, followed by an MDT on two curative-intent cases of pancreatic cancer.

Early biliary tract and liver cancer

Thank you to AstraZeneca for sponsoring this session.

with review by Prof Marc Besselink

Abstract presented: Targeting drug-resistant hepatocellular carcinoma with microRNA-based therapeutics – Tasnuva Kabir

The final focus of the day was early biliary tract and liver cancer, opening with Dr Kathy Kyung You’s talk on equity in Australian cancer clinical trials. This was followed by a radiation oncology keynote by Prof Laura Dawson titled Rising Role of Radiation Therapy for the Treatment of Liver Cancer and an MDT debate comprising of a surgical case and a translational case.

The day ended with the Welcome Reception in the Exhibition Hall.


Go to: Day 1 | Day 2 | Day 3 | Day 4 | Image gallery